{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:10:37Z","timestamp":1789593037920,"version":"build-2803163510"},"reference-count":117,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014042","name":"US Department of Defense Peer Reviewed Cancer Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","award":["TRAN1-16050"],"award-info":[{"award-number":["TRAN1-16050"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","award":["DISC2-13015"],"award-info":[{"award-number":["DISC2-13015"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","award":["DISC2-11157"],"award-info":[{"award-number":["DISC2-11157"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","award":["TRAN1-12250"],"award-info":[{"award-number":["TRAN1-12250"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.xcrm.2026.102998","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:47:51Z","timestamp":1787150871000},"page":"102998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Scalable generation of hematopoietic stem cell-engineered off-the-shelf mono-specific cytotoxic T cells targeting solid tumors"],"prefix":"10.1016","volume":"7","author":[{"given":"Yichen","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaji","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zibai","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enbo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel S.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Hon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9858-300X","authenticated-orcid":false,"given":"Yan-Ruide","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102998_bib1","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1172\/JCI32446","article-title":"Adoptive T cell therapy for cancer in the clinic","volume":"117","author":"June","year":"2007","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.102998_bib2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41576-021-00329-9","article-title":"Genetic engineering of T cells for immunotherapy","volume":"22","author":"Ellis","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.xcrm.2026.102998_bib3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102998_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: State of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xcrm.2026.102998_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nri2887","article-title":"Mechanisms for T cell receptor triggering","volume":"11","author":"Van Der Merwe","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2026.102998_bib6","doi-asserted-by":"crossref","first-page":"15772","DOI":"10.18632\/oncotarget.4694","article-title":"Oncogenic cancer\/testis antigens: prime candidates for immunotherapy","volume":"6","author":"Gjerstorff","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2026.102998_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molonc.2011.02.001","article-title":"The biology of cancer testis antigens: putative function, regulation and therapeutic potential","volume":"5","author":"Fratta","year":"2011","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102998_bib8","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nrurol.2012.117","article-title":"Cancer\/testis antigens and urological malignancies","volume":"9","author":"Kulkarni","year":"2012","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.xcrm.2026.102998_bib9","first-page":"731","article-title":"FDA approves first TCR-engineered T cell therapy, for rare soft-tissue cancer","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.102998_bib10","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of cancer: current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102998_bib11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1006\/jsre.2001.6148","article-title":"NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma","volume":"98","author":"Goydos","year":"2001","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.xcrm.2026.102998_bib12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.humpath.2013.05.029","article-title":"Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma","volume":"45","author":"Aung","year":"2014","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.xcrm.2026.102998_bib13","first-page":"19","article-title":"Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer","volume":"3","author":"Sharma","year":"2003","journal-title":"Cancer Immun."},{"key":"10.1016\/j.xcrm.2026.102998_bib14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12967-020-02306-y","article-title":"Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy","volume":"18","author":"Raza","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102998_bib15","doi-asserted-by":"crossref","first-page":"e44707","DOI":"10.1371\/journal.pone.0044707","article-title":"A Novel HLA-B18 Restricted CD8+ T Cell Epitope Is Efficiently Cross-Presented by Dendritic Cells from Soluble Tumor Antigen","volume":"7","author":"Zhao","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102998_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/5cdf6105-2a52-497a-86b3-db8f4a4e439c","article-title":"NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer","volume":"7","author":"Ademuyiwa","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102998_bib17","doi-asserted-by":"crossref","first-page":"E10702","DOI":"10.1073\/pnas.1810653115","article-title":"Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules","volume":"115","author":"Bethune","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102998_bib18","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1158\/1078-0432.CCR-23-1456","article-title":"Safety and efficacy of NY-ESO-1 antigen-specific T-cell receptor gene-transduced T lymphocytes in patients with synovial sarcoma: a phase I\/II clinical trial","volume":"29","author":"Kawai","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102998_bib19","article-title":"Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A\u2217 02: 01 patients with advanced soft tissue sarcoma","volume":"4","author":"Pan","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.102998_bib20","series-title":"A Phase I\/IIa, Open Label, Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients with Recurrent or Treatment Refractory Ovarian Cancer (NCT01567891)","author":"Odunsi","year":"2017"},{"key":"10.1016\/j.xcrm.2026.102998_bib21","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1\u2013specific TCR\u2013engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102998_bib22","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102998_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41416-018-0327-z","article-title":"The clinical role of the TME in solid cancer","volume":"120","author":"Giraldo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102998_bib24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3390\/organoids1020012","article-title":"3D tumor spheroid and organoid to model tumor microenvironment for cancer immunotherapy","volume":"1","author":"Zhu","year":"2022","journal-title":"Organoids"},{"key":"10.1016\/j.xcrm.2026.102998_bib25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nm.4015","article-title":"Prospects for gene-engineered T cell immunotherapy for solid cancers","volume":"22","author":"Klebanoff","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102998_bib26","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s12015-019-09901-7","article-title":"Solid tumors challenges and new insights of CAR T cell engineering","volume":"15","author":"Tahmasebi","year":"2019","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.xcrm.2026.102998_bib27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fimmu.2013.00363","article-title":"TCR-engineered T cells meet new challenges to treat solid tumors: choice of antigen, T cell fitness, and sensitization of tumor milieu","volume":"4","author":"Kunert","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102998_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2018.02.004","article-title":"Targeting the microenvironment in solid tumors","volume":"65","author":"Belli","year":"2018","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.xcrm.2026.102998_bib29","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jnci\/djm135","article-title":"Drug resistance and the solid tumor microenvironment","volume":"99","author":"Tr\u00e9dan","year":"2007","journal-title":"JNCI Journal of the National Cancer Institute"},{"key":"10.1016\/j.xcrm.2026.102998_bib30","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1002\/acg2.86","article-title":"Toward \u201coff-the-shelf\u201d allogeneic CAR T cells","volume":"3","author":"Aftab","year":"2020","journal-title":"Adv. Cell Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102998_bib31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41571-024-00959-y","article-title":"Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks","volume":"22","author":"Diorio","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102998_bib32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.102998_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003811","article-title":"NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome","volume":"10","author":"Ishihara","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102998_bib34","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41587-019-0137-8","article-title":"Gene editing for immune cell therapies","volume":"37","author":"Bailey","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.102998_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.xcrm.2026.102998_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215736","article-title":"Gene knockout in cellular immunotherapy: Application and limitations","volume":"540","author":"Zhang","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.xcrm.2026.102998_bib37","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable manufacturing of CAR T cells for cancer immunotherapy","volume":"2","author":"Abou-el-Enein","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102998_bib38","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","article-title":"Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method","volume":"43","author":"Li","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.102998_bib39","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.stem.2012.11.002","article-title":"Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation","volume":"12","author":"Nishimura","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.xcrm.2026.102998_bib40","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.102998_bib41","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.4237","article-title":"Generation of mature T cells from human hematopoietic stem and progenitor cells in artificial thymic organoids","volume":"14","author":"Seet","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2026.102998_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5618","article-title":"iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti\u2013PD-1 therapy","volume":"12","author":"Cichocki","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102998_bib43","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","article-title":"Transgenic expression of IL15 improves antiglioma activity of IL13R\u03b12-CAR T cells but results in antigen loss variants","volume":"5","author":"Krenciute","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2026.102998_bib44","doi-asserted-by":"crossref","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102998_bib45","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","article-title":"NKT cells coexpressing a GD2-specific chimeric antigen receptor and IL15 show enhancedin vivo persistence and antitumor activity against neuroblastoma","volume":"25","author":"Xu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102998_bib46","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102998_bib47","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102998_bib48","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.molmed.2025.05.014","article-title":"IL-15 in CAR engineering: striking an efficacy\u2013safety balance","volume":"31","author":"Li","year":"2025","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.xcrm.2026.102998_bib49","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.trecan.2021.08.004","article-title":"Engineering stem cells for cancer immunotherapy","volume":"7","author":"Li","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.xcrm.2026.102998_bib50","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/mt.2013.8","article-title":"Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem\/progenitor cells","volume":"21","author":"Giannoni","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102998_bib51","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.stem.2023.02.009","article-title":"Advancing cell-based cancer immunotherapy through stem cell engineering","volume":"30","author":"Li","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.xcrm.2026.102998_bib52","article-title":"Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy","volume":"10","author":"Chen","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.xcrm.2026.102998_bib53","article-title":"TCR-T immunotherapy: the challenges and solutions","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2026.102998_bib54","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nm.2128","article-title":"Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy","volume":"16","author":"Bendle","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102998_bib55","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nm.2700","article-title":"Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer","volume":"18","author":"Provasi","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102998_bib56","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1089\/hum.2023.128","article-title":"Genome editing in engineered T cells for cancer immunotherapy","volume":"34","author":"Bonini","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102998_bib57","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","article-title":"Breakthrough of solid tumor treatment: CAR-NK immunotherapy","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.xcrm.2026.102998_bib58","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12929-024-00998-8","article-title":"Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies","volume":"31","author":"Li","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.xcrm.2026.102998_bib59","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102998_bib60","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.102998_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003715","article-title":"T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion","volume":"10","author":"Morton","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102998_bib62","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1073\/pnas.1003345107","article-title":"Tumor-infiltrating NY-ESO-1\u2013specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer","volume":"107","author":"Matsuzaki","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102998_bib63","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ygyno.2017.03.509","article-title":"NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer","volume":"145","author":"Szender","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102998_bib64","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/s41467-025-56270-6","article-title":"Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies","volume":"16","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102998_bib65","article-title":"Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers","volume":"25","author":"Li","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.xcrm.2026.102998_bib66","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ymthe.2019.04.001","article-title":"Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma","volume":"27","author":"Sommer","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102998_bib67","article-title":"Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy","volume":"2","author":"Li","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.102998_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe6474","article-title":"Pan-cancer single-cell landscape of tumor-infiltrating T cells","volume":"374","author":"Zheng","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102998_bib69","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","article-title":"Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma","volume":"176","author":"Li","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102998_bib70","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41586-024-07762-w","article-title":"Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission","volume":"634","author":"Bai","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102998_bib71","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","article-title":"An NK-like CAR T cell transition in CAR T cell dysfunction","volume":"184","author":"Good","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102998_bib72","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102998_bib73","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002709","article-title":"CD8+ TILs in NSCLC differentiate into TEMRA via a bifurcated trajectory: deciphering immunogenicity of tumor antigens","volume":"9","author":"Lee","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102998_bib74","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/s41598-019-39345-5","article-title":"Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment","volume":"9","author":"Iwahori","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2026.102998_bib75","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.cell.2023.02.021","article-title":"Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes","volume":"186","author":"Rahim","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102998_bib76","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","article-title":"Lineage tracking reveals dynamic relationships of T cells in colorectal cancer","volume":"564","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102998_bib77","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","article-title":"CAR T cell combination therapies to treat cancer","volume":"42","author":"Uslu","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102998_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1368732","article-title":"Prospects and challenges of CAR-T cell therapy combined with ICIs","volume":"14","author":"Lv","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2026.102998_bib79","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41571-019-0182-8","article-title":"The NKG2A immune checkpoint\u2014a new direction in cancer immunotherapy","volume":"16","author":"Creelan","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102998_bib80","article-title":"Implications of NKG2A in immunity and immune-mediated diseases","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102998_bib81","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.cell.2018.10.028","article-title":"NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines","volume":"175","author":"van Montfoort","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102998_bib82","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI123955","article-title":"Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells","volume":"129","author":"Kamiya","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.102998_bib83","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andr\u00e9","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102998_bib84","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202317804","article-title":"Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies","volume":"15","author":"Melero","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.xcrm.2026.102998_bib85","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s40425-019-0761-3","article-title":"Monalizumab: inhibiting the novel immune checkpoint NKG2A","volume":"7","author":"Van Hall","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102998_bib86","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.3389\/fimmu.2018.03041","article-title":"Strategies for enhancing and preserving anti-leukemia effects without aggravating graft-versus-host disease","volume":"9","author":"Chang","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102998_bib87","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nri2000","article-title":"Graft-versus-host disease","volume":"7","author":"Shlomchik","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2026.102998_bib88","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat8410","article-title":"Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF\u2013licensed myeloid cells","volume":"10","author":"Tugues","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102998_bib89","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/35869","article-title":"HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C","volume":"391","author":"Braud","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102998_bib90","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41577-019-0200-1","article-title":"Engineering universal cells that evade immune detection","volume":"19","author":"Lanza","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2026.102998_bib91","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102998_bib92","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102998_bib93","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102998_bib94","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102998_bib95","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","article-title":"The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy","volume":"8","author":"Paul","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102998_bib96","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","article-title":"Toward eliminating HLA class I expression to generate universal cells from allogeneic donors","volume":"122","author":"Torikai","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102998_bib97","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev-immunol-102119-073227","article-title":"Current concepts and advances in graft-versus-host disease immunology","volume":"39","author":"Hill","year":"2021","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2026.102998_bib98","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41590-018-0051-0","article-title":"Single-cell gene expression reveals a landscape of regulatory T cell phenotypes shaped by the TCR","volume":"19","author":"Zemmour","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2026.102998_bib99","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.ymthe.2024.04.005","article-title":"Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy","volume":"32","author":"Li","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.102998_bib100","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1158\/0008-5472.CAN-14-0376","article-title":"HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice","volume":"74","author":"Gschweng","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102998_bib101","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/hematology.2020002547","article-title":"Next-generation cell therapies: the emerging role of CAR-NK cells","author":"Basar","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.xcrm.2026.102998_bib102","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.xcrm.2026.102998_bib103","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41467-020-20658-3","article-title":"A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy","volume":"12","author":"Iriguchi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102998_bib104","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2018-99-111356","article-title":"Preliminary data on safety, cellular kinetics and anti-leukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a pool of adult and pediatric patients with high-risk CD19+ relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"132","author":"Benjamin","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102998_bib105","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102998_bib106","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102998_bib107","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102998_bib108","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.stem.2015.03.011","article-title":"New Cell Sources for T Cell Engineering and Adoptive Immunotherapy","volume":"16","author":"Themeli","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.xcrm.2026.102998_bib109","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.stem.2025.05.007","article-title":"Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy","volume":"32","author":"Hosking","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.xcrm.2026.102998_bib110","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2024-208634","article-title":"Generation of Functional iPSC-Derived CAR-T Cells for Cancer Immunotherapy Via G9a\/GLP Inhibition","volume":"144","author":"Jing","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102998_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101517","article-title":"Development of iPSC-derived T cells targeting EGFR neoantigens in non-small cell lung cancer","volume":"33","author":"Niizuma","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2026.102998_bib112","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11899-019-00528-6","article-title":"Induced Pluripotent Stem Cell (iPSC)\u2013Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges","volume":"14","author":"Nianias","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.xcrm.2026.102998_bib113","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2012.12.006","article-title":"Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8+ T cells","volume":"12","author":"Vizcardo","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.xcrm.2026.102998_bib114","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.stem.2019.08.004","article-title":"Development of hematopoietic stem cell-engineered invariant natural killer T cell therapy for cancer","volume":"25","author":"Zhu","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.xcrm.2026.102998_bib115","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1073\/pnas.1424877112","article-title":"Genetic engineering of hematopoietic stem cells to generate invariant natural killer T cells","volume":"112","author":"Smith","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102998_bib116","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.trecan.2025.06.008","article-title":"IL-18 revives dysfunctional CAR-T cells","volume":"11","author":"Li","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.xcrm.2026.102998_bib117","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-026-02602-x","article-title":"Spatiotemporal profiling reveals distinct dynamics and checkpoint regulations of CAR-T and CAR-NKT cells against solid tumors","volume":"11","author":"Li","year":"2026","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126004155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126004155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:46:51Z","timestamp":1789591611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126004155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":117,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666379126004155"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102998","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Scalable generation of hematopoietic stem cell-engineered off-the-shelf mono-specific cytotoxic T cells targeting solid tumors","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102998","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102998"}}